David L. Brinkley

Worldwide Team Leader for Viagra at Pfizer Inc

Location:
235 E 42ND ST, New York City, New York, United States
Company:
Pfizer Inc
HQ Phone:
(212) 733-2323
Wrong David Brinkley?

Last Updated 7/17/2014

General Information

Employment History

JMC IT Mahal Pvt.Ltd

Head of Business Development  - Innoviva Inc

Various Management Positions  - GlaxoSmithKline plc

Education

B.A.  - International Relations , Kent State University

M.A. with honors  - International Economics , School of Advanced International Studies of the Johns Hopkins University

Affiliations

Board Member  - Aratana Therapeutics Inc

Board Member  - Ziarco Pharma Ltd

Realtor  - Terra Firma Global Partners Inc

Head of Business Development  - Theravance , Inc.

Web References  

Ziarco Appoints David L. Brinkley to the Board of Directors::Global Pharmaceutical Technology :: A leading B2B, Media Portal for Pharmaceutical Industry.

Ziarco Appoints David L. Brinkley to the Board of Directors
Ziarco Appoints David L. Brinkley to the Board of Directors::Global Pharmaceutical Technology :: A leading B2B, Media Portal for Pharmaceutical Industry. Ziarco Appoints David L. Brinkley to the Board of Directors a biopharmaceutical company focusing on steroid-unresponsive inflammation and allergic diseases, has appointed the experienced pharma professional and recent Head of Business Development at Theravance, Mr. David Brinkley, to its board of directors. His role at Ziarco will be to provide input on the company's corporate, R&D strategy and business plans. Commenting on his appointment, Mr. Brinkley said: "Ziarco's assets have strong potential to yield differentiated, important new medicines to address unmet needs of patients across a spectrum of disorders. I look forward to assisting in the growth and success of the company." Ziarco's CEO, Dr Mike Yeadon, commented: "We are delighted that David has joined our board and is providing valuable advice to the team. Mr. Brinkley was Head of Business Development from November 2008 to July 2013 and had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007, when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc. leading the team that had full responsibility for the U.S. and subsequent global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham's Animal Health operations and was Director of new product planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline from 1983 to 1995. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.

Read More
Aratana | Board of Directors

David L. Brinkley
David Brinkley worked for Theravance, Inc., a biopharmaceutical company, from 2000 to 2013, most recently as the Head of Business Development from November 2008 to July 2013. Mr. Brinkley had previously served as Senior Vice President, Commercial Development at Theravance when he left to start a consulting practice in 2007. Prior to that, he served as Worldwide Team Leader for Viagra at Pfizer Inc., leading the team that had full responsibility for the global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham's Animal Health operations and was Director of new product planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline Animal Health from 1983 to 1995. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.

Read More
http://www.sec.gov/Archives/edgar/data/1509190/0001509190-16-000070.txt

The current Class I Directors are Laura A. Brege, Robert Rip Gerber and Wendy L. Yarno; the current Class II Directors are Irvine Irv O. Hockaday, Esq., Merilee Raines and John Vander Vort, Esq.; and the current Class III Directors are David Brinkley, Robert P. Roche and Steven St. Peter, M.D.
David L. Brinkley David L. Brinkley David L. Brinkley has been a member of our Board of Directors since March 2014. Mr. Brinkley worked for Theravance, Inc., a publicly-traded biopharmaceutical company, from 2000 to 2013, most recently as the Head of Business Development from November 2008 to July 2013. Mr. Brinkley had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007, when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc., leading the team that had full responsibility for the global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beechams Animal Health operations and was Director of New Product Planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline Animal Health from 1983 to 1995. Mr. Brinkley previously served on the Board of Directors of Ziarco Pharma Ltd., a privately-held pharmaceutical company. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors. We believe Mr. Brinkley is qualified to serve on our Board due to his extensive leadership experience in the biopharmaceutical industry, including his roles at Theravance and Pfizer. David L. Brinkley Our Board of Directors currently consists of 9 members: Laura A. Brege, David L. Brinkley, Robert Rip Gerber, Irvine Irv O. Hockaday, Esq., Merilee Raines, Robert P. Roche, Steven St. Peter, M.D., John Vander Vort, Esq. and Wendy L. Yarno. Brinkley and Robert P. Roche, Class III Director nominees elected to the Board in 2014, were recommended by the Chief Executive Officer and a non-management director, respectively.

Read More

Browse ZoomInfo’s Directories